Liver fibrosis happens when persistent inflammation of the liver causes excessive scar tissue to build up in the organ and nearby blood vessels. The presence of scar tissue can impair overall liver ...

Liver fibrosis may be diagnosed and staged — no fibrosis (stage F0), mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) — with the use of clinical parameters and ...

Liver fibrosis is the buildup of scar tissue in the liver, the organ that helps you digest food, store energy, and remove toxins. Liver fibrosis occurs as the organ tries to repair itself from ...

In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...

The U.S. Food and Drug Administration (FDA) has approved the first medicine to treat a common liver disease known as nonalcoholic steatohepatitis, also called fatty liver disease. Regulators have ...

Researchers have discovered previously unknown changes in a specific type of liver cells, potentially opening avenues for a new treatment for liver fibrosis, a potentially life-threatening condition.

An Akero Therapeutics drug in development for the fatty liver disease MASH now has clinical trial results showing the experimental treatment reversed organ scarring, bringing patients back from an ...

Liver fibrosis is a progressive and potentially reversible condition that results from chronic liver damage, which can be caused by a variety of factors, including metabolic dysfunction-associated ...